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Abstract— Aims:Managing patients with alcohol dependence includes assessment for heavy drinking, typically by asking patients. Some
recommend biomarkers to detect heavy drinking but evidence of accuracy is limited. Methods: Among people with dependence, we
assessed the performance of disialo-carbohydrate-deficient transferrin (%dCDT, ≥1.7%), gamma-glutamyltransferase (GGT, ≥66 U/l), either
%dCDT or GGT positive, and breath alcohol (> 0) for identifying 3 self-reported heavy drinking levels: any heavy drinking (≥4 drinks/day
or >7 drinks/week for women, ≥5 drinks/day or >14 drinks/week for men), recurrent (≥5 drinks/day on ≥5 days) and persistent heavy drink-
ing (≥5 drinks/day on ≥7 consecutive days). Subjects (n = 402) with dependence and current heavy drinking were referred to primary care
and assessed 6 months later with biomarkers and validated self-reported calendar method assessment of past 30-day alcohol use. Results:
The self-reported prevalence of any, recurrent and persistent heavy drinking was 54, 34 and 17%. Sensitivity of %dCDT for detecting any,
recurrent and persistent self-reported heavy drinking was 41, 53 and 66%. Specificity was 96, 90 and 84%, respectively. %dCDT had higher
sensitivity than GGT and breath test for each alcohol use level but was not adequately sensitive to detect heavy drinking (missing 34–59%
of the cases). Either %dCDT or GGT positive improved sensitivity but not to satisfactory levels, and specificity decreased. Neither a breath
test nor GGT was sufficiently sensitive (both tests missed 70–80% of cases). Conclusions: Although biomarkers may provide some useful
information, their sensitivity is low the incremental value over self-report in clinical settings is questionable.
INTRODUCTION
Managing patients with chronic alcohol dependence includes
assessment for heavy drinking and relapse, typically achieved
by asking patients (McLellan et al., 2000; McLellan, 2002;
Saitz et al., 2008). Biomarkers have been suggested as a way to
detect heavy drinking and relapse (a return to heavy drinking
after a period with no heavy use) (Neumann and Spies, 2003).
There are various biomarkers of alcohol use. Alcohol can
be measured in the blood, breath or urine. Because of its short
half-life of alcohol, the window of assessment for alcohol in
these samples is brief, and therefore these tests may miss
drinking that is not very recent. Nevertheless, these measures
may be useful because they are not invasive and can provide
‘point of service’ rapid results. Other options include measures
of tissue damage and/or physiological responses caused by
alcohol. These indirect measures of alcohol use usually have
longer windows of assessment but are likely to be influenced
by factors other than alcohol use itself.
To be useful to clinicians in real life situations, any blood
test or biomarker must have adequate accuracy, reflected by its
sensitivity and specificity, and adequate positive and negative
predictive values.
Carbohydrate-deficient transferrin (CDT) is considered the
most specific biomarker used clinically for detecting heavy
alcohol use and monitoring abstinence during treatment
(Salaspuro, 1999; Anton, 2001; Arndt, 2001; Anton et al.,
2002; Golka and Wiese, 2004; Schwan et al., 2004;Hannuksela
et al., 2007). Its performance appears to be less affected by liver
diseases than are liver enzyme markers used to detect heavy
alcohol consumption (Anttila et al., 2003; Fleming et al., 2004;
Arndt et al., 2006; Bortolotti et al., 2006). There is also a dose–
response relationship between alcohol use and CDT levels
(Sillanaukee et al., 2000; Schellenberg et al., 2005). Burke and
colleagues found that a 10% change in CDT had 70% sensitiv-
ity and 80% specificity for detecting changes of at least 2
drinks/day in men (Burke et al., 1998). CDT has also been con-
sidered for detecting relapse or heavy drinking among people
with alcohol dependence (Allen et al., 2001). One study sug-
gests that a rise in CDT level can herald a relapse self-reported
by the patient, and therefore be of clinical interest to detect
relapse (Mitchell et al., 1997). Disialo-carbohydrate-deficient
transferrin (measured as %dCDT) is the CDT isoform reported
to be the most specific for heavy alcohol use.
Another commonly used test in clinical practice to detect
heavy drinking is the serum gamma-glutamyl-transferase
(GGT). GGT appears to be less sensitive and specific than
CDT but, because it is relatively independent of CDT, com-
bining the two tests may improve sensitivity (Conigrave et al.,
2002;Neumann and Spies, 2003;Hannuksela et al., 2007).
Nevertheless, there is a lack of data on the operating
characteristics of biomarkers outside of test validation studies,
in which participants are recruited based on their alcohol con-
sumption to establish the tests operating characteristics, or
studies conducted among patients following specialized treat-
ment programs. These studies provide crucial information on
biomarkers operating characteristics but are less informative
with respect to broader clinical samples such as patients with
alcohol dependence seen in primary health care settings.
Knowing the operating characteristics of biomarkers to detect
any heavy use among people with dependence that are not in
treatment per se, a situation encountered in general health care
settings, would be useful to clinicians.
In the present study, we assessed the operating characteristics
of these tests for identifying heavy drinking among people
with dependence: disialo-carbohydrate-deficient transferrin
Alcohol and Alcoholism Vol. 49, No. 4, pp. 423–429, 2014 doi: 10.1093/alcalc/agu016
Advance Access Publication 15 April 2014
© The Author 2014. Medical Council on Alcohol and Oxford University Press. All rights reserved
 at U
niversitÃ© & EPFL Lausanne on July 15, 2014
http://alcalc.oxfordjournals.org/
D
ow
nloaded from
 
(%dCDT), gamma-glutamyltransferase (GGT), %dCDT and
GGT together, and breath alcohol.
METHODS
We used cross-sectional data from 402 adults with alcohol
dependence and current heavy drinking at study entry. This
study is a secondary analysis of data collected for the Addiction
Health Evaluation And Disease management (AHEAD) study
(Saitz et al., 2013).The AHEAD study aimed to evaluate the ef-
fectiveness of a chronic disease management program providing
integrated health services for alcohol and other drug depend-
ence in primary care. Participants were recruited between
September 2006 and September 2008 primarily from a free-
standing residential detoxification unit in Boston, MA, USA, as
well as from self- and physician referrals from a large urban
teaching hospital and through local advertisements. None of the
participants entered the study through the acute internal medi-
cine hospital, but two participants were referred to enroll in this
outpatient study after a hospitalization. Participants were eli-
gible if they were 18 years of age or older, fluent in English or
Spanish, had alcohol or drug dependence, reported drinking ≥4
standard drinks for women and ≥5 standard drinks for men at
least twice, or ≥15 drinks per week for women and ≥22 drinks
per week for men in an average week in the past 30 days or
recent illicit drug use, provided 2 contacts to assist with follow-
up, had no plans to move from the local area within a year of
screening and a score >21 on Mini-Mental State Examination
(i.e. no serious cognitive impairment) (Folstein et al., 1975;
Smith et al., 2006). People were excluded if they were not
able to provide informed consent, were pregnant or had
breath alcohol >100 mg/dl. The study was approved by the
Institutional Review Board at Boston University Medical
Campus (BUMC IRB). All participants were referred to
primary care and received information to give to their primary
care provider.
For the present study we used data from AHEAD partici-
pants who reported drinking ≥4 standard drinks for women or
≥5 standard drinks for men at least twice, or ≥15 drinks per
week for women and ≥22 drinks per week for men in an
average week in the past 30 days and had alcohol dependence
[determined using the Composite International Diagnostic
Interview Short Form (CIDI-SF)] at study entry. Other base-
line instruments included: the Addiction Severity Index (ASI)
(McLellan et al., 1992), the Short From Health Survey
(SF-12v2) (Ware et al., 1996) and the Katz comorbidity ques-
tionnaire (Katz et al., 1996).
Assessments of alcohol use by interview and biomarkers
were performed at the study follow-up visits. Follow-up visits
took place 3, 6 and 12 months after the baseline assessment
but blood tests for biomarkers were only performed at the
6-month visit (or at the 12-month visit if missed at the
6-month visit). Past 30-day alcohol consumption was deter-
mined using the Timeline Followback, a validated structured
calendar method (Sobell and Sobell, 1995), at the same visit
as the biomarker testing. The Timeline Followback is a widely
used and accepted reference standard, particularly when admi-
nistered by trained personnel and with assurances of confiden-
tiality. For substance use, the Timeline Followback has
demonstrated good test-retest reliability (Sobell et al., 1986,
2001; Fals-Stewart et al., 2000; Carey et al., 2004). Its
agreement with other self-report measures of alcohol use is
good (Grant et al., 1995; Seale et al., 2006; Johnson-Greene
et al., 2009). It has been shown to be correlated with reports
by patient’s collaterals (Sobell and Sobell, 1992). The present
study includes only those participants with assessments of
alcohol use by both interview and biomarker.
Biomarkers
CDT was measured as %dCDT using a cutoff point of ≥1.7%
to define a positive test. The assay, based on high-pressure
liquid chromatography with spectrophotometric detection,
focuses solely on one isoform, the disialo-transferrin. We used
cutoff values recommended by the Medical University of
South Carolina, Institute of Psychiatry, Clinical Neurobiology
Laboratory, Charleston, SC (where the samples were ana-
lyzed). GGT positive cutoff point was defined as: ≥66 U/l (the
upper limit of normal in the laboratory where the samples
were tested). We also used a combination of the two tests
(either %dCDT or GGT or both positive). A positive breath
alcohol test was >0. We also measured aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) and com-
puted the AST/ALT ratio, a potential marker of alcohol intake
(but one that has been questioned since it may also indicate
advanced alcoholic liver disease rather than heavy drinking),
and used two different cutoffs: AST/ALT>1.5, AST/ALT>2.0
(Salaspuro, 1987;Nyblom et al., 2004).
Primary analyses
We assessed the operating characteristics of %dCDT (≥1.7),
GGT (≥66 U/l), a combination of %dCDT-GGT (either or
both positive), and breath alcohol (>0) for identifying the
following three self-reported alcohol use levels over the past
30 days (determined using the Timeline Followback as the
reference standard):
(1) any heavy drinking (≥4 drinks in a day or >7 drinks/
week for women, ≥5 drinks in a day or >14 drinks/
week for men),
(2) recurrent heavy drinking (≥5 drinks in a day on at least
5 days)
(3) persistent heavy drinking (≥5 drinks in a day on at
least 7 consecutive days).
Sensitivity, specificity and corresponding exact 95% confi-
dence intervals were calculated for each of the four biomarker
tests to detect the three heavy alcohol use levels.
Receiver operating characteristic (ROC) curves were esti-
mated to summarize the accuracy of %dCDT, GGT, as well as
to evaluate the optimal cutoff points for distinguishing sub-
jects with any, recurrent and persistent self-reported heavy
drinking. Optimal cutoff points were determined by maximiz-
ing the combination of sensitivity and specificity. The area
under the ROC curve (AUC) was used to quantify the overall
accuracy of each test (1.0 represents a perfect test and 0.5
represents a test that cannot discriminate better than chance).
Positive and negative predictive values (PPV, NPV), and like-
lihood ratio positive and negative (LR+, LR−) were also esti-
mated along with 95% confidence intervals (calculated using
published formulas) (Altman and Gardner, 1992).
424 Bertholet et al.
 at U
niversitÃ© & EPFL Lausanne on July 15, 2014
http://alcalc.oxfordjournals.org/
D
ow
nloaded from
 
Secondary analyses
Sensitivity and specificity of AST/ALT (with two cutoffs:
>1.5 and >2.0) were estimated for comparison with %dCDT
and GGT. ROC curves were estimated to summarize the accur-
acy of AST/ALT.
Because gender and BMI may affect the performance of
biomarkers, the analyses were repeated stratified by gender
and BMI (≤30 vs. >30).
All analyses were performed using SAS version 9.1.3
(Cary, NC, USA).
RESULTS
Based on the study aims (i.e. detecting heavy drinking among
patients with alcohol dependence), we selected among
AHEAD study participants (n = 569) those who had alcohol
dependence and heavy drinking (past 30 days) at baseline (n =
402). Baseline characteristics of this study’s analytic sample
(n = 374) as well as alcohol use data at follow-up (i.e. 6 or 12
month depending when the tests were available for each par-
ticipant) are presented in Table 1.
By self-report reference standard, the prevalence of any, re-
current and persistent heavy drinking at follow-up was 54.1
33.9, and 16.8%, respectively.
Primary analyses
The estimated sensitivity, specificity, positive predictive and
negative predictive values of %dCDT (at cutoff point of
≥1.7%), GGT (for ≥66 U/l), combination test (either or both
positive), and breath alcohol (>0) to identify any, recurrent,
and persistent self-reported heavy drinking are presented in
Table 2; %dCDT alone had higher sensitivity than GGT and
breath alcohol test for each alcohol use level. Nevertheless, the
test missed 34–59% of the cases. The combination of %dCDT
and GGT appeared to improve sensitivity but specificity
decreased.
Likelihood ratios positive and negative are presented in
Table 3 (a likelihood ratio positive is the probability of a
person who has the disease testing positive divided by the
probability of a person who does not have the disease testing
positive. A likelihood ratio negative is the probability of a
person who has the disease testing negative divided by the
probability of a person who does not have the disease testing
Table 2. Performance of biomarkers to detect three self-reported heavy alcohol use levels
Target condition and test N Sensitivity % (95% CI)a Specificity PPV NPV
Any heavy drinking
%dCDT 356 40.7 (33.7, 48.0) 95.7 (91.3, 98.3) 91.9 (83.9, 96.7) 57.4 (51.3, 63.4)
GGT 361 20.0 (14.6, 26.3) 86.1 (79.9, 91.0) 62.9 (49.7, 74.8) 47.8 (42.0, 53.7)
Either %dCDT+ or GGT+ 358 52.6 (45.3, 59.8) 82.3 (75.6, 87.8) 77.9 (69.8, 84.7) 59.5 (52.8, 65.9)
Breath alcohol 375 19.9 (14.6, 26.1) 96.6 (92.7, 98.7) 87.0 (73.7, 95.1) 51.1 (45.5, 56.6)
Recurrent heavy drinking
%dCDT 356 52.5 (43.2, 61.7) 90.3 (85.7, 93.7) 73.3 (62.6, 82.2) 78.9 (73.5, 83.6)
GGT 361 19.3 (12.7, 27.6) 83.9 (78.6, 88.3) 37.1 (25.2, 50.3) 67.9 (62.3, 73.2)
Either %dCDT+ or GGT+ 358 60.0 (50.7, 68.8) 75.2 (69.2, 80.6) 55.0 (46.0, 63.7) 78.9 (73.0, 84.0)
Breath alcohol 375 26.0 (18.5, 34.7) 94.4 (90.9, 96.9) 69.6 (54.3, 82.3) 72.3 (67.2, 77.1)
Persistent heavy drinking
%dCDT 356 66.1 (52.6, 77.9) 84.2 (79.5, 88.1) 45.4 (34.6, 56.5) 92.6 (88.8, 95.4)
GGT 361 29.3 (18.1, 42.7) 85.1 (80.6, 89.0) 27.4 (16.9, 40.2) 86.3 (81.9, 90.0)
Either %dCDT+ or GGT+ 358 74.6 (61.6, 85.0) 70.9 (65.4, 76.0) 33.6 (25.6, 42.4) 93.4 (89.3, 96.3)
Breath alcohol 375 30.7 (19.6, 43.7) 91.4 (87.7, 94.2) 41.3 (27.0, 56.8) 86.9 (82.8, 90.4)
Any heavy drinking was defined as ≥4 drinks per occasion or >7 drinks per week for women, ≥5 drinks per occasion or >14 per week for men. Recurrent heavy
drinking was defined as ≥5 drinks per day on at least 5 days over the past 30 days. Persistent heavy drinking was defined as ≥5 drinks per day on at least 7
consecutive days over the past 30 days.
aExact 95% CI (confidence interval).
Table 1. Characteristics of study participants
Baseline sample characteristics (n = 402)
Age, mean (SD) 40.0 (9.8)
Female, n (%) 100 (24.9%)
Homelessness (1+ night/past 3 months), n (%) 259 (64.4%)
Unemployed, n (%) 173 (43.0%)
Marital status, married, n (%) 25 (6.2%)
Education level (<High School, HS, >HS) 23.6%/48.8%/27.6%
Race ethnicity, n (%)
Non-Hispanic white 160 (39.8%)
Non-Hispanic black 152 (37.8%)
Hispanic 59 (14.7%)
Non-Hispanic other 31 (7.7%)
Alcohol use, past 30 days
Number of drinks per week, median (25th, 75th) 61.7 (25.9; 119.7)
Drinks/drinking day, median (25th, 75th) 14.6 (9.0; 23.4)
Maximum drinks in 1 day, median (25th, 75th) 24.0 (14.0; 39.0)
Percent days abstinent, median (25th, 75th) 25.0 (0.0; 66.7)
Any binge drinking, n (%) 400 (99.5%)
Current tobacco use, n (%) 360 (89.6%)
Heroin, cocaine or marijuana use, past 30 days, n (%) 344 (85.6%)
HCV infectiona 159 (39.9%)
SF-12 Physical Component Summary, mean (SD) 41.5 (8.4)
SF-12 Mental Component Summary, mean (SD) 30.5 (9.8)
Addiction Severity Index—alcohol, mean (SD) 0.6 (0.3)
Addiction Severity Index—drugs, mean (SD) 0.3 (0.2)
Katz comorbidity scale, lifetime, mean (SD) 0.8 (1.1)
Alcohol use at follow-up (n = 374)b
Number of drinks per week, median (25th, 75th) 2.5 (0.0; 25.2)
Drinks/drinking day, median (25th, 75th) 4.5 (0.0; 11.0)
Maximum drinks in one day, median (25th, 75th) 6.0 (0.0; 14.0)
Percent days abstinent, median (25th, 75th) 93.3 (56.7; 100.0)
Any binge drinking, n (%) 202 (54.0%)
SF-12: Short Form Health Survey v2.
aHCV status was based on antibody testing and/or viral load testing results.
The majority of the sample (401/402, 99.8%) was antibody tested, and of
those, 47.7% (84/176) who tested seropositive had results confirmed with
HCV viral load testing.
bi.e. 6 or 12 month depending when the tests were available for each
participant.
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negative); %dCDT appeared to have the best likelihood ratio
positive for each alcohol use level, followed next by breath
alcohol. A likelihood ratio positive >5 has been used to indi-
cate a moderate to large increase in the odds of the disease if
the test is positive and, similarly, a likelihood ratio negative
<0.2 suggests a moderate to large decrease in the odds of the
disease if the test is negative (Jaeschke et al., 1994). Two
tests, %dCDT (9.47) and breath alcohol (5.85), had estimated
likelihood ratios positive >5 for detecting any heavy drinking,
although the lower bounds of the 95% confidence intervals
were below the threshold. For the detection of recurrent heavy
drinking, only %dCDT had an estimated likelihood ratio posi-
tive >5 (5.41). No test had a likelihood ratio positive >5 for
persistent heavy drinking. Across the three different levels of
heavy drinking, no test had a likelihood ratio negative <0.2.
We assessed whether or not false positives for %dCDT, GGT
and AST/ALT were corroborated by the other tests. Among the
false positive biomarker cases, most (41/50, 82%) were not cor-
roborated by the other tests: among the false positive CDT
cases (n = 7), 1 case was corroborated by a positive GGT test;
among the false positive GGT cases (n = 23), 1 case was corro-
borated by a positive CDT test; 2 cases were corroborated by a
positive breath alcohol content test; among the false positive
AST/ALT >1.5 cases (n = 17), 1 case was corroborated by a
positive CDT test, 1 case was corroborated by a positive breath
alcohol content test, and 2 cases were corroborated by a positive
GGT test; among the false positive AST/ALT >2.0 cases
(n = 3), 1 case was corroborated by a positive GGT test.
Optimal cutoff points and test accuracy for %dCDT and GGT
The ROC curves for %dCDT gave the following optimal
cutoff points for any, recurrent and persistent self-reported
heavy drinking, respectively: 1.5% (sensitivity: 50.5%; speci-
ficity: 90.1%); 1.3% (sensitivity: 75.8%; specificity: 69.1%);
1.4% (sensitivity: 81.4%; specificity: 69.7%). The estimated
area under the curve (AUC) suggests fair to good accuracy of
the test.
Optimal cutoff points for GGT were: 24 IU/l (sensitivity:
71.8%; specificity: 48.8%); 27 IU/l (sensitivity: 75.6%; speci-
ficity: 54.1%); 40 IU/l (sensitivity: 55.2%; specificity 70.3%).
The estimated area under the curve (AUC) suggests poor
accuracy of the test.
Estimated area under the curve, optimal cutoff points and
corresponding sensitivity and specificity for %dCDT and
GGT are presented in Table 4.
Secondary analyses
AST/ALT
Sensitivity (95% confidence interval, CI) for AST/ALT >1.5
was 14.8% (10.1%; 20.6%), 16.3% (10.2%; 24.0%) and
21.3% (11.9%; 33.7%) to detect any, recurrent and persistent
self-reported heavy drinking. Corresponding specificity (95%
CI) was 89.8% (84.1%; 93.9%), 89.2% (84.5%; 92.8%) and
89.1% (85.0%; 92.4%), respectively.
Sensitivity (95% CI) for AST/ALT >2 was 3.1% (1.1%;
6.5%), 2.4% (0.5%; 7.0%) and 4.9% (1.0%; 13.7%) to detect
any, recurrent and persistent self-reported heavy drinking.
Corresponding specificity was 98.2% (94.8%; 99.6%), 97.5%
(94.6%; 99.1%) and 98.0% (95.7%; 99.3%).
The ROC curves for the AST/ALT ratio gave the following
optimal cutoff points for any, recurrent and persistent self-
reported heavy drinking, respectively: 1.08 (sensitivity:
56.1%; specificity: 59.0%); 1.08 (sensitivity: 60.2%; specifi-
city: 56.3%); 1.21 (sensitivity: 54.1%; specificity: 67.2%).
The estimated area under the curve (AUC) suggests unaccept-
able accuracy of the test.
Estimated area under the curve, optimal cutoff points and
corresponding sensitivity and specificity for the AST/ALT
ratio are presented in Table 4.
Stratified analyses by gender and BMI
Stratified analyses by gender and BMI are presented in
Table 5. In general, sensitivity appeared slightly better for
men compared with women. Larger differences were observed
Table 3. Likelihood ratios positive and negative for three self-reported heavy
alcohol use levels
Target condition and test
Likelihood ratio+
(95% CI)
Likelihood ratio−
(95% CI)
Any heavy drinking
%dCDT 9.42 (4.48, 19.84) 0.62 (0.55, 0.70)
GGT 1.44 (0.90, 2.31) 0.93 (0.85, 1.02)
%dCDT+ or GGT+ 2.97 (2.08, 4.25) 0.58 (0.49, 0.68)
Breath alcohol 5.77 (2.51, 13.28) 0.83 (77.0, 89.4)
Recurrent heavy drinking
%dCDT 5.39 (3.53, 8.23) 0.53 (0.43, 0.64)
GGT 1.20 (0.75, 1.91) 0.96 (0.87, 1.07)
%dCDT+ or GGT+ 2.42 (1.86, 3.16) 0.53 (0.42, 0.67)
Breath alcohol 4.68 (2.60, 8.45) 0.78 (0.70, 0.87)
Persistent heavy drinking
%dCDT 4.18 (3.03, 5.75) 0.40 (0.28, 0.58)
GGT 1.97 (1.22, 3.20) 0.83 (0.70, 0.99)
%dCDT+ or GGT+ 2.56 (2.03, 3.23) 0.36 (0.23, 0.56)
Breath alcohol 3.55 (2.11, 5.97) 0.76 (0.64, 0.90)
Any heavy drinking was defined as ≥4 drinks per occasion or >7 drinks per
week for women, ≥5 drinks per occasion or >14 per week for men; Recurrent
heavy drinking was defined as ≥5 drinks per day on at least 5 days over the
past 30 days; Persistent heavy drinking was defined as ≥5 drinks per day on at
least 7 consecutive days over the past 30 days.
CI, confidence interval.
Table 4. Optimal cutoff points with sensitivity and specificity, and area under
the curve (AUC) for %dCDT, GGT and AST/ALT for three self-reported
heavy alcohol use levels
Optimal
cutoff point
Sensitivity for
optimal cutoff
point (%)
Specificity for
optimal cutoff
point (%) AUC
Any heavy drinking
%dCDT 1.5% 50.5 90.1 0.77
GGT 24 IU/l 71.8 48.8 0.61
AST/ALT 1.08 56.1 59.0 0.59
Recurrent heavy drinking
%dCDT 1.3% 75.8 69.1 0.80
GGT 27 IU/l 75.6 54.1 0.64
AST/ALT 1.08 60.2 56.3 0.59
Persistent heavy drinking
%dCDT 1.4% 81.4 69.7 0.81
GGT 40 IU/l 55.2 70.3 0.66
AST/ALT 1.21 54.1 67.2 0.61
Any heavy drinking was defined as ≥4 drinks per occasion or >7 drinks per
week for women, ≥5 drinks per occasion or >14 per week for men; Recurrent
heavy drinking was defined as ≥5 drinks per day on at least 5 days over the
past 30 days; Persistent heavy drinking was defined as ≥5 drinks per day on at
least 7 consecutive days over the past 30 days.
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by BMI status: %dCDT and breath alcohol appeared to be
more sensitive among individuals with BMI ≤ 30 compared
with those with BMI > 30. Tests were generally more specific
for women and for people with BMI > 30.
DISCUSSION
We aimed at investigating the accuracy and operating
characteristics of blood and breath tests (i.e. biomarkers) for
detecting heavy drinking in individuals with alcohol depend-
ence who were followed for 6 to 12 months after being en-
rolled with current heavy drinking. We used self-reported
validated calendar measures of alcohol use from the Timeline
Followback as the reference standard. Among individuals with
alcohol dependence, %dCDT yielded the best performance.
The estimated likelihood ratio positive for %dCDT suggests
that a positive test may be associated with a moderate to large
increase in the odds of any heavy drinking and recurrent
heavy drinking in this population. Nevertheless, at the recom-
mended cutoff point for %dCDT, almost 60% of individuals
reporting heavy drinking amounts were not identified. The
sensitivity of the tests were marginally better when %dCDT
and GGT results were combined: when %dCDT was com-
bined with GGT, 25% of individuals reporting drinking five or
more drinks on at least 7 consecutive days in the past month
were not identified. Specificity appeared to decrease for the
combined test compared with either test alone. Therefore,
while a positive test might be useful to detect or herald relapse
(Mitchell et al., 1997), the %dCDT test will miss most cases,
making the test of little use in clinical practice.
The breath alcohol test and GGT missed 70–80% of the
cases. Both GGT and breath alcohol test detect approximately
only one in five cases of heavy drinking. As such, both tests
were very insensitive for detecting any heavy drinking
reported by the TLFB. Breath alcohol is generally assumed to
be poor for detecting drinking over time (since it only detects
recent drinking). GGT is thought to be useful for detecting
heavy drinking even when drinking has not occurred in recent
hours. Combining these two tests would not be much more
clinically useful (since at best, assuming that they never detect
the same patients, they would detect two in five cases).
The specificity of the studied biomarkers was adequate, but,
given the prevalence of drinking in the population, negative
predictive values indicate the biomarkers were clinically
useful only for the highest drinking category. In addition, the
Table 5. Performance of biomarkers to detect three self-reported heavy alcohol use levels, stratified by gender and BMI
Gender Male Female
Target condition and test N Sensitivity % (95% CI) Specificity % (95% CI) N Sensitivity % (95% CI) Specificity % (95% CI)
Any heavy drinking
%dCDT 274 42.4 (34.6, 50.5) 94.8 (89.1, 98.1) 82 33.3 (18.6, 51.0) 97.8 (88.5, 99.9)
GGT 277 23.3 (16.9, 30.6) 82.2 (74.1, 88.6) 84 5.6 (0.7, 18.7) 95.8 (85.8, 99.5)
%dCDT+ or GGT+ 276 56.3 (48.2, 64.2) 78.0 (69.4, 85.1) 82 36.1 (20.8, 53.8) 93.5 (82.1, 98.6)
Breath alcohol 280 20.9 (14.9, 27.9) 95.7 (90.3, 98.6) 95 15.8 (6.0, 31.3) 98.3 (90.6, 100.0)
Recurrent heavy drinking
%dCDT 274 53.3 (43.3, 63.1) 89.9 (84.4, 94.0) 82 46.7 (21.3, 73.4) 91.0 (81.5, 96.6)
GGT 277 20.2 (13.0, 29.2) 78.6 (71.8, 84.5) 84 13.3 (1.7, 40.5) 97.1 (89.9, 99.7)
%dCDT+ or GGT+ 276 60.9 (50.9, 70.3) 70.2 (62.7, 76.9) 82 53.3 (26.6, 78.7) 88.1 (77.8, 94.7)
Breath alcohol 280 26.4 (18.3, 35.9) 93.7 (89.0, 96.8) 95 23.5 (6.8, 49.9) 96.2 (89.2, 99.2)
Persistent heavy drinking
%dCDT 274 66.7 (52.1, 79.2) 82.5 (76.9, 87.3) 82 62.5 (24.5, 91.5) 89.2 (79.8, 95.2)
GGT 277 30.0 (17.9, 44.6) 81.1 (75.3, 85.9) 84 25.0 (3.2, 65.1) 97.4 (90.8, 99.7)
%dCDT+ or GGT+ 276 74.5 (60.4, 85.7) 65.8 (59.2, 71.9) 82 75.0 (34.9, 96.8) 86.5 (76.6, 93.3)
Breath alcohol 280 29.6 (18.0, 43.6) 89.8 (85.1, 93.4) 95 37.5 (8.5, 75.5) 95.4 (88.6, 98.7)
BMI BMI ≤30 BMI >30
Target condition and test Sensitivity % (95%CI) Specificity % (95%CI) Sensitivity % (95%CI) Specificity % (95%CI)
Any heavy drinking
%dCDT 255 46.7 (38.2, 55.4) 94.9 (89.3, 98.1) 95 27.3 (16.1, 41.0) 97.5 (86.8, 99.9)
GGT 258 19.9 (13.5, 27.6) 83.6 (75.8, 89.7) 97 19.3 (10.1, 31.9) 97.5 (86.8, 99.9)
%dCDT+ or GGT+ 257 56.9 (48.2, 65.4) 79.2 (70.8, 86.0) 95 41.8 (28.7, 55.9) 95.0 (83.1, 99.4)
Breath alcohol 265 21.7 (15.2, 29.6) 98.4 (94.4, 99.8) 103 14.8 (7.0, 26.2) 95.2 (83.8, 99.4)
Recurrent heavy drinking
%dCDT 255 61.5 (50.1, 71.9) 88.9 (83.3, 93.2) 95 32.4 (18.0, 50.0) 93.1 (83.3, 98.1)
GGT 258 19.5 (11.6, 29.7) 82.4 (75.9, 87.7) 97 18.9 (8.0, 35.2) 91.7 (81.6, 97.2)
%dCDT+ or GGT+ 257 67.5 (56.3, 77.4) 73.0 (65.8, 79.4) 95 43.2 (27.1, 60.5) 84.5 (72.6, 92.7)
Breath alcohol 265 30.5 (20.8, 41.6) 96.2 (92.3, 98.5) 103 17.1 (7.2, 32.1) 93.6 (84.3, 98.2)
Persistent heavy drinking
%dCDT 255 70.7 (54.5, 83.9) 80.8 (74.9, 85.9) 95 55.6 (30.8, 78.5) 92.2 (83.8, 97.1)
GGT 258 30.0 (16.6, 46.5) 83.9 (78.4, 88.6) 97 27.8 (9.7, 53.5) 91.1 (82.6, 96.4)
%dCDT+ or GGT+ 257 78.1 (62.4, 89.4) 67.1 (60.4, 73.4) 95 66.7 (41.0, 86.7) 83.1 (72.9, 90.7)
Breath alcohol 265 39.0 (24.2, 55.5) 92.9 (88.7, 95.9) 103 14.3 (3.1, 36.3) 90.2 (81.7, 95.7)
Any heavy drinking was defined as ≥4 drinks per occasion or >7 drinks per week for women, ≥5 drinks per occasion or >14 per week for men; Recurrent heavy
drinking was defined as ≥5 drinks per day on at least 5 days over the past 30 days; Persistent heavy drinking was defined as ≥5 drinks per day on at least 7
consecutive days over the past 30 days.
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challenge for clinicians is to detect individuals who are drink-
ing heavily and therefore sensitivity is more critical, which is
different from other testing situations where specificity is key
(i.e. forensic testing).
Optimal cutoffs for %dCDT were roughly similar to the
recommended cutoffs by the testing laboratory. For GGT,
optimal cutoffs were very different from cutoffs used clinical-
ly. The optimal cutoff points (24, 27 and 40 U/l for any, recur-
rent and persistent self-reported heavy drinking) are below
what is considered abnormal in a clinical setting (66 U/l) and
general accuracy of the test was limited, making it inadvisable
for clinicians to choose to use GGT by itself to detect heavy
drinking.
In general, in ROC analyses, areas under the curve were fair
to good for %dCDT but not for other tests. For example the
performance of AST/ALT was close to what we would expect
if the test performed no better than chance.
Observed sensitivity and specificity for %dCDT were in the
mid-upper range of those reported in previous studies con-
ducted in various populations and with various methods of
testing (Koch et al., 2004). In their systematic review, Koch
et al. reported on two CDT assays (CDTect and CDTTriTIA)
with sensitivity ranging from 10 to 85% and specificity from
77 to 100%. As shown in other studies, combining CDT and
GGT increased sensitivity (Sillanaukee and Olsson, 2001).
The simple combination of the two tests (either or both test
positive) allows sensitivities in the 50–75% range (depending
on the targeted drinking level). Nevertheless, the combination
of the two tests, in terms of accuracy, does not appear suffi-
ciently valuable.
The present study has limitations. The reference standard
used in the present study should not be considered equivalent
to a short clinical assessment of alcohol use or to self-report in
response to unstructured questions The TLFB is an extensive
procedure that is unlikely to be implemented in clinical prac-
tice. Therefore our findings do not necessarily inform how
laboratory tests compare to the usual shorter and likely less re-
liable questions used in clinical practice to identify heavy
drinking. Nevertheless, the TLFB has shown good agreement
with shorter self-report instruments of alcohol use (Seale
et al., 2006; Johnson-Greene et al., 2009). In the present
study, the TLFB was used as a reference standard to under-
stand the potential clinical utility of laboratory tests.
Also, a strong effort was made to insure confidentiality.
This is appropriate when studying sensitivity and other operat-
ing characteristics, but may differ from what would occur in
clinical practice. Therefore our results should not be inter-
preted as a comparison between biomarkers and self-report as
it is likely to occur in day-to-day clinical practice. In the
present study, we have a real world clinical population in
terms of their risk for heavy drinking, but with the advantage
of the research situation with respect to measuring the refer-
ence standard for heavy drinking (validated calendar method,
assurances of confidentiality). Therefore, the research situation
maximizes the likelihood of accurate reporting of heavy drink-
ing. This is a strength of the study, since it removes one of the
main justifications for testing (i.e. the fact that patient might
not report accurately their drinking) and gives information on
how reliable biomarkers are when accuracy of self-report is
maximized. In some cases, biomarkers were positive when the
self-report was not. We do not have enough information to de-
termine whether or not these tests were false elevations due to
something else or whether they allowed identifying heavy
drinking in subjects who did not self-report it. Numbers were
small and in most cases, one positive biomarker result was not
corroborated by the other tests. Despite the limitation in being
able to interpret reasons for false positives and false negatives,
the main focus and findings of this paper remain highly clinic-
ally relevant—in informing the question of how well can
laboratory tests can detect reference standard self-reported
heavy drinking.
Another limitation is that we did not test all possible bio-
markers, such as phosphatidylethanol (PeTH) and ethylglucur-
onide (EtG), tests that are not in routine clinical use (Helander
et al., 2012; Kharbouche et al., 2012). These biomarkers are
promising but appropriate cutoffs are still being determined.
There is hope that they may be better in detecting heavy drink-
ing, though further research is needed—the biggest challenge
being whether they can distinguish heavy drinking from any
drinking. Despite limitations, we think our study provides im-
portant insights for clinicians about widely available tests:
from a clinical point of view, even though %dCDT alone is
not very sensitive, it can perform adequately. When facing a
positive %dCDT test, positive predictive values were accept-
able to good for the two lowest levels of drinking. Due to the
lower prevalence of the highest drinking category, positive
predictive value was 45%. Therefore, %dCDT may have better
predictive value for detecting heavier levels of drinking than
the ones reported here but the positive predictive value will be
greatly affected due to the very limited prevalence of heaviest
drinking levels, even in a population that consisted of indivi-
duals with quite severe alcohol dependence. Furthermore,
most would agree that it is important to be able to detect all of
the three heavy drinking levels we defined in this study when
managing patients with alcohol dependence.
In conclusion, biomarkers have been recommended for
assessing return to heavy drinking in people with alcohol de-
pendence in treatment. However, the tests do not appear to
perform sufficiently well enough as stand-alone tests. In our
data, even if we speculate that all the participants who had a
positive %dCDT test and reported no heavy use were not
reporting their alcohol use (i.e. making the assumption that the
test has NO false positives), only 7/356 additional subjects
would have been picked up by the test. Therefore, our findings
do not support their use at this time.
A carefully taken history of alcohol use is likely to provide
more useful information than lab testing, even though, as
stated in the limitations paragraph, clinicians are not expected
to use a TLFB procedure with their patients. Also the question
remains as to how to intervene clinically among those report-
ing no heavy use whose tests are positive. Challenging patient
reports is delicate and can negatively impact the doctor–
patient relationship, especially since false positive blood tests
are possible and even likely. As a result we think that biomar-
kers have potential on occasion to bring useful additional in-
formation to clinicians in the detection of heavy drinking
among patients with dependence, but this is likely to be the ex-
ception rather than the rule. Such use should occur with dis-
cussion with the patient in the context of a supportive doctor–
patient relationship, where discrepancies between self-report
and lab-tests results can be discussed. With regard to research
settings, the biomarkers we have studied do not appear to have
sufficient diagnostic accuracy for identifying heavy alcohol
use to be used as stand-alone tests.
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